Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains

[1]  E. De Clercq,et al.  Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806. , 2014, European journal of medicinal chemistry.

[2]  W. Spreen,et al.  Long-acting injectable antiretrovirals for HIV treatment and prevention , 2013, Current opinion in HIV and AIDS.

[3]  I. Georgiev,et al.  Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. , 2013, Current opinion in HIV and AIDS.

[4]  S. Fruehauf.  Current Clinical Indications for Plerixafor , 2013, Transfusion Medicine and Hemotherapy.

[5]  Adam Godzik,et al.  A Blueprint for HIV Vaccine Discovery. , 2012, Cell host & microbe.

[6]  L. Furci,et al.  Inhibition of HIV-1 Infection by Human α-Defensin-5, a Natural Antimicrobial Peptide Expressed in the Genital and Intestinal Mucosae , 2012, PloS one.

[7]  A. d’Arminio Monforte,et al.  Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. , 2012, The Journal of antimicrobial chemotherapy.

[8]  T. Lavé,et al.  Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors , 2012, Antimicrobial Agents and Chemotherapy.

[9]  L. Lopalco,et al.  Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4 , 2011, PloS one.

[10]  S. Matsushita,et al.  CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. , 2010, Bioorganic & medicinal chemistry letters.

[11]  A. Coutsoudis,et al.  Prevention of vertical transmission of HIV-1 in resource-limited settings , 2010, Expert review of anti-infective therapy.

[12]  A. García-Sastre,et al.  An enzymatic virus-like particle assay for sensitive detection of virus entry. , 2010, Journal of virological methods.

[13]  C. Rouzioux,et al.  High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. , 2009, The Journal of antimicrobial chemotherapy.

[14]  B. Clotet,et al.  A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. , 2009, The Journal of infectious diseases.

[15]  D. Montefiori,et al.  Evidence that Ecotropic Murine Leukemia Virus Contamination in TZM-bl Cells Does Not Affect the Outcome of Neutralizing Antibody Assays with Human Immunodeficiency Virus Type 1 , 2009, Journal of Virology.

[16]  E. Clercq,et al.  Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. , 2009, International journal of antimicrobial agents.

[17]  J. Kostman,et al.  Relationship Between HIV Coreceptor Tropism and Disease Progression in Persons With Untreated Chronic HIV Infection , 2009, Journal of acquired immune deficiency syndromes.

[18]  J. Sodroski,et al.  Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. , 2008, Structure.

[19]  Bernard Hirschel,et al.  Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. , 2008, The New England journal of medicine.

[20]  Eoin Coakley,et al.  HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  P. Biswas,et al.  Monocyte‐derived macrophages and myeloid cell lines as targets of HIV‐1 replication and persistence , 2006, Journal of leukocyte biology.

[22]  David W. Williamson,et al.  Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. , 2006, The Journal of infectious diseases.

[23]  N. Graham,et al.  HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. , 2006, The Journal of infectious diseases.

[24]  A. Lazzarin,et al.  Oral CCR5 inhibitors: will they make it through? , 2006, Expert opinion on investigational drugs.

[25]  P. Lusso,et al.  HIV and the chemokine system: 10 years later , 2006, The EMBO journal.

[26]  Michael S Saag,et al.  Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 , 2005, Nature Medicine.

[27]  P. Harrigan,et al.  Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. , 2005, The Journal of infectious diseases.

[28]  B. Gazzard,et al.  Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.

[29]  Wayne A Hendrickson,et al.  Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Christine Katlama,et al.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.

[31]  E. Berger,et al.  Vaccinia‐Based Reporter Gene Cell‐Fusion Assays to Quantitate Functional Interactions of HIV Envelope Glycoprotein with Receptors , 2003, Current protocols in immunology.

[32]  H. Kleinman,et al.  Suradista NSC 651016 inhibits the angiogenic activity of CXCL12-stromal cell-derived factor 1alpha. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Peter D. Kwong,et al.  The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120 , 2002, Journal of Virology.

[34]  H. Groen,et al.  PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  S. Zolla-Pazner,et al.  Inhibition of Human Immunodeficiency Virus Type 1 gp120 Presentation to CD4 T Cells by Antibodies Specific for the CD4 Binding Domain of gp120 , 2001, Journal of Virology.

[36]  M. Malnati,et al.  CD46 Is a Cellular Receptor for Human Herpesvirus 6 , 1999, Cell.

[37]  M. Hollingshead,et al.  Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. , 1998, Journal of medicinal chemistry.

[38]  G. Boiteau,et al.  J. Virol. Methods , 1996, Journal of Virological Methods.

[39]  R. Kiser,et al.  Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. , 1995, Antiviral research.

[40]  M. Reitz,et al.  Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1 , 1995, Journal of virology.

[41]  A. Fauci,et al.  Cross-linking of CD30 induces HIV expression in chronically infected T cells. , 1995, Immunity.

[42]  J. Fantini,et al.  Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. , 1994, The Journal of biological chemistry.

[43]  C. Broder,et al.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation , 1994, Journal of virology.

[44]  J. Justement,et al.  Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells , 1992, The Journal of experimental medicine.

[45]  Q. Sattentau,et al.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4. , 1990, Science.

[46]  P. Volberding,et al.  Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group. , 1987, JAMA.

[47]  E. Gelmann,et al.  EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO , 1985, The Lancet.

[48]  R. Warnke,et al.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. , 1984, Cancer research.

[49]  S. Matsushita,et al.  Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. , 1984, Science.

[50]  A. Galizzi,et al.  Genetic and Physiological Studies on the Site of Action of Distamycin A , 1975, Antimicrobial Agents and Chemotherapy.

[51]  S. Penco,et al.  Structure and Synthesis of Distamycin A , 1964, Nature.

[52]  A. Wormall,et al.  Studies on suramin; the action of the drug on some enzymes. , 1950, The Biochemical journal.

[53]  A. Wormall,et al.  Action of Suramin on Enzymes , 1949, Nature.

[54]  Nico Eisenhauer,et al.  10 years later: Revisiting priorities for science and society a decade after the Millennium Ecosystem Assessment , 2015 .

[55]  Louis Valiquette,et al.  10 years later... , 2013, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[56]  A. Lazzarin,et al.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development. , 2005, Drugs.

[57]  E. de Clercq.  Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. , 1979, Cancer letters.